Search Results - "Davidson, NE"

Estrogen Carcinogenesis in Breast Cancer by Yager, James D, Davidson, Nancy E

“…Estrogen exposure is a major determinant of the risk of breast cancer. This article reviews how genotoxic, mutagenic metabolites of estrogen and stimulation of…”
Get full text

Effects of ovarian ablation or suppression on breast cancer recurrence and survival: Patient-level meta-analysis of 14,993 pre-menopausal women in 25 randomized trials by Gray, Richard G., Bradley, Rosie, Braybrooke, Jeremy, Clarke, Mike, Hills, Robert Kerrin, Peto, Richard, Bergh, Jonas C. S., Swain, Sandra M., Davidson, Nancy E., Francis, Prudence A., Regan, Meredith M.

“…503 Background: Suppressing ovarian function of women with breast cancer may improve outcome by preventing estrogenic stimulation of any residual cancer,…”
Get full text

Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer by Romond, Edward H, Perez, Edith A, Bryant, John, Suman, Vera J, Geyer, Charles E, Davidson, Nancy E, Tan-Chiu, Elizabeth, Martino, Silvana, Paik, Soonmyung, Kaufman, Peter A, Swain, Sandra M, Pisansky, Thomas M, Fehrenbacher, Louis, Kutteh, Leila A, Vogel, Victor G, Visscher, Daniel W, Yothers, Greg, Jenkins, Robert B, Brown, Ann M, Dakhil, Shaker R, Mamounas, Eleftherios P, Lingle, Wilma L, Klein, Pamela M, Ingle, James N, Wolmark, Norman

“…A combined analysis of two large studies found that the addition of trastuzumab to chemotherapy with doxorubicin and cyclophosphamide plus paclitaxel improved…”
Get full text

Anticancer activities of novel chalcone and bis-chalcone derivatives by Modzelewska, Aneta, Pettit, Catherine, Achanta, Geetha, Davidson, Nancy E., Huang, Peng, Khan, Saeed R.

“…Novel chalcone and bis-chalcone derivatives have been synthesized and evaluated for antitumor activity. These molecules inhibited the growth of the human…”
Get full text

Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques by ROSS, A. A, COOPER, B. W, WINTER, C, AKARD, L, JANSEN, J, COPELAN, E, MEAGHER, R. C, HERZIG, R. H, KLUMPP, T. R, KAHN, D. G, WARNER, N. E, LAZARUS, H. M, MACKAY, W, MOSS, T. J, CIOBANU, N, TALLMAN, M. S, KENNEDY, M. J, DAVIDSON, N. E, SWEET, D

“…Although peripheral blood stem cell collections (PBSC) are thought to have less tumor involvement than bone marrow (BM), the incidence of circulating tumor…”
Get full text

Abstract PD7-02: Novel human cell line xenograft models of ERα-positive metastatic invasive lobular breast carcinoma as pre-clinical platforms for validating candidate genetic drivers by Tasdemir, N, Scott, J, Laotche, J, Hou, W, Bossart, EA, Atkinson, J, Sflomos, G, Sreekumar, S, Castro, C, Anderson, C, Lee, AV, Brisken, C, Lucas, PC, Davidson, NE, Oesterreich, S

“…Abstract Invasive lobular breast carcinoma (ILC) is the second most common subtype of breast cancer following invasive ductal breast carcinoma, accounting for…”
Get full text

A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer by Goss, Paul E, Ingle, James N, Martino, Silvana, Robert, Nicholas J, Muss, Hyman B, Piccart, Martine J, Castiglione, Monica, Tu, Dongsheng, Shepherd, Lois E, Pritchard, Kathleen I, Livingston, Robert B, Davidson, Nancy E, Norton, Larry, Perez, Edith A, Abrams, Jeffrey S, Therasse, Patrick, Palmer, Michael J, Pater, Joseph L

“…Postmenopausal women with early breast cancer who have undergone successful initial therapy receive five years of treatment with tamoxifen, an antagonist of…”
Get full text

The biology of breast carcinoma by Keen, Judith Clancy, Davidson, Nancy E.

“…The biology of breast carcinoma is complex, with multiple factors contributing to its development and progression. The current review focuses on the role of…”
Get full text

Abstract GS2-03: Highly recurrent transcriptional remodeling events in advanced endocrine resistant ER-positive breast cancers by Priedigkeit, N, Vareslija, D, Basudan, A, Watters, RJ, Lucas, PC, Davidson, NE, Blohmer, J-U, Denkert, C, Machleidt, A, Heppner, BI, Brufsky, AM, Oesterreich, S, Young, L, Lee, AV

“…Abstract BACKGROUND: Although individual cancers are driven by heterogeneous processes, cancer mortality has a near universal cause—therapy resistance,…”
Get full text

Restoration of tamoxifen sensitivity in estrogen receptor-negative breast cancer cells : Tamoxifen-bound reactivated ER recruits distinctive corepressor complexes by SHARMA, Dipali, SAXENA, Neeraj K, DAVIDSON, Nancy E, VERTINO, Paula M

“…Breast tumors expressing estrogen receptor-alpha (ER) respond well to therapeutic strategies using selective ER modulators, such as tamoxifen. However,…”
Get full text

Exercise manages fatigue during breast cancer treatment: A randomized controlled trial by Mock, Victoria, Frangakis, Constantine, Davidson, Nancy E., Ropka, Mary E., Pickett, Mary, Poniatowski, Barbara, Stewart, Kerry J., Cameron, Lane, Zawacki, Kristin, Podewils, Laura J., Cohen, Gary, McCorkle, Ruth

“…Fatigue is the most prevalent and debilitating symptom experienced by breast cancer patients receiving adjuvant chemotherapy or radiation therapy and few…”
Get full text

Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741 by CITRON, Marc L, BERRY, Donald A, PEREZ, Edith A, CARPENTER, John, HURD, David, HOLLAND, James F, SMITH, Barbara L, SARTOR, Carolyn I, LEUNG, Eleanor H, ABRAMS, Jeffrey, SCHILSKY, Richard L, MUSS, Hyman B, CIRRINCIONE, Constance, NORTON, Larry, HUDIS, Clifford, WINER, Eric P, GRADISHAR, William J, DAVIDSON, Nancy E, MARTINO, Silvana, LIVINGSTON, Robert, INGLE, James N

“…Using a 2 x 2 factorial design, we studied the adjuvant chemotherapy of women with axillary node-positive breast cancer to compare sequential doxorubicin (A),…”
Get full text

Abstract PD7-03: Investigating cortactin as a genetic driver of disease progression in invasive lobular carcinoma by Tasdemir, N, Sikora, MJ, Zhu, L, Levine, KM, Scott, J, Basudan, A, Sflomos, G, Sreekumar, S, Bossart, EA, Elishaev, E, Chandran, UR, Tseng, GC, Jankowitz, RC, Dabbs, DJ, McAuliffe, PF, Brisken, C, Davidson, NE, Oesterreich, S

“…Abstract Invasive lobular carcinoma (ILC) is the second most common type of breast cancer following invasive ductal carcinoma (IDC) and accounts for 10-15% of…”
Get full text

Design, Synthesis, and Evaluation of Novel Boronic-Chalcone Derivatives as Antitumor Agents by Kumar, Srinivas K, Hager, Erin, Pettit, Catherine, Gurulingappa, Hallur, Davidson, Nancy E, Khan, Saeed R

“…A series of boronic-chalcone derivatives were synthesized and tested for antitumor activity against human breast cancer cell lines. The results show the…”
Get full text

Release of Methyl CpG Binding Proteins and Histone Deacetylase 1 from the Estrogen Receptor α (ER) Promoter upon Reactivation in ER-Negative Human Breast Cancer Cells by Sharma, Dipali, Blum, Julie, Yang, Xiaowei, Beaulieu, Normand, Macleod, A. Robert, Davidson, Nancy E

“…Estrogen receptor α (ER) is an epigenetically regulated gene. Inhibitors of DNA methyltransferases (DNMTs) and histone deacetylases (HDACs) synergistically…”
Get full text

Chemoendocrine Therapy for Premenopausal Women With Axillary Lymph Node–Positive, Steroid Hormone Receptor–Positive Breast Cancer: Results From INT 0101 (E5188) by DAVIDSON, Nancy E, O'NEILL, Anne M, VUKOV, Allen M, OSBORNE, C. Kent, MARTINO, Silvana, WHITE, Douglas R, ABELOFF, Martin D

“…Chemotherapy, tamoxifen, and ovarian ablation/suppression (OA/OS) are effective adjuvant approaches for premenopausal, steroid hormone receptor-positive breast…”
Get full text

Abstract GS4-03: Randomized comparison of adjuvant tamoxifen (T) plus ovarian function suppression (OFS) versus tamoxifen in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): Update of the SOFT trial by Fleming, G, Francis, PA, Láng, I, Ciruelos, EM, Bellet, M, Bonnefoi, HR, Climent, MA, Pavesi, L, Burstein, HJ, Martino, S, Davidson, NE, Geyer, CE, Walley, BA, Coleman, RE, Kerbrat, P, Buchholz, S, Ingle, JN, Rabaglio-Poretti, M, Colleoni, M, Regan, MM

“…Abstract Background: The primary results of SOFT at 5.6 years median follow-up found adding OFS to T did not provide a significant benefit in the overall study…”
Get full text

Randomized Phase III Trial of Marimastat Versus Placebo in Patients With Metastatic Breast Cancer Who Have Responding or Stable Disease After First-Line Chemotherapy: Eastern Cooperative Oncology Group Trial E2196 by SPARANO, Joseph A, BERNARDO, Patricia, STEPHENSON, Patricia, GRADISHAR, William J, INGLE, James N, ZUCKER, Stanley, DAVIDSON, Nancy E

“…To determine whether a matrix metalloproteinase inhibitor improves progression-free survival (PFS) in patients with metastatic breast cancer who have…”
Get full text

Synergistic activation of functional estrogen receptor (ER)-α by DNA methyltransferase and histone deacetylase inhibition in human er-α-negative breast cancer cells by XIAOWEI YANG, PHILLIPS, Dawn L, FERGUSON, Anne T, NELSON, William G, HERMAN, James G, DAVIDSON, Nancy E

“…Formation of transcriptional repression complexes such as DNA methyltransferase (DNMT) 1/histone deacetylase (HDAC) or methyl-CpG binding protein/HDAC is…”
Get full text

Abstract P6-08-02: Developing in vitro models of ductal carcinoma in situ from primary tissue by McAuliffe, PF, Brown, DD, Oesterreich, S, Lee, AV, Johnson, RR, McGuire, KP, Davidson, NE, Brufsky, AM, Dabbs, DJ

“…Abstract BACKGROUND: Because there are currently no reliable predictors for progression of ductal carcinoma in situ (DCIS) to invasive disease, nearly all…”
Get full text